We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know
Read MoreHide Full Article
In the latest close session, Boston Scientific (BSX - Free Report) was down 1.27% at $48.34. The stock exceeded the S&P 500, which registered a loss of 1.62% for the day. On the other hand, the Dow registered a loss of 1.87%, and the technology-centric Nasdaq decreased by 1.98%.
The medical device manufacturer's stock has dropped by 9.5% in the past month, falling short of the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.83, showcasing a 10.67% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $5.4 billion, showing a 6.63% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.36 per share and a revenue of $21.64 billion, representing changes of +9.8% and +7.81%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.34% lower. Boston Scientific is currently sporting a Zacks Rank of #5 (Strong Sell).
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 14.55. Its industry sports an average Forward P/E of 17.7, so one might conclude that Boston Scientific is trading at a discount comparatively.
One should further note that BSX currently holds a PEG ratio of 0.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 1.58 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 164, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know
In the latest close session, Boston Scientific (BSX - Free Report) was down 1.27% at $48.34. The stock exceeded the S&P 500, which registered a loss of 1.62% for the day. On the other hand, the Dow registered a loss of 1.87%, and the technology-centric Nasdaq decreased by 1.98%.
The medical device manufacturer's stock has dropped by 9.5% in the past month, falling short of the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.83, showcasing a 10.67% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $5.4 billion, showing a 6.63% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.36 per share and a revenue of $21.64 billion, representing changes of +9.8% and +7.81%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.34% lower. Boston Scientific is currently sporting a Zacks Rank of #5 (Strong Sell).
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 14.55. Its industry sports an average Forward P/E of 17.7, so one might conclude that Boston Scientific is trading at a discount comparatively.
One should further note that BSX currently holds a PEG ratio of 0.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 1.58 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 164, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.